Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective
about
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patientsNew developments and controversies in iron metabolism and iron chelation therapy.Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature.Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom.Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.
P2860
Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-utility analysis of defer ...... ron overload: a UK perspective
@en
Cost-utility analysis of defer ...... on overload: a UK perspective.
@nl
type
label
Cost-utility analysis of defer ...... ron overload: a UK perspective
@en
Cost-utility analysis of defer ...... on overload: a UK perspective.
@nl
prefLabel
Cost-utility analysis of defer ...... ron overload: a UK perspective
@en
Cost-utility analysis of defer ...... on overload: a UK perspective.
@nl
P2093
P2860
P1433
P1476
Cost-utility analysis of defer ...... ron overload: a UK perspective
@en
P2093
Anthony Bentley
Fernando Tricta
John Connelly
Michael Spino
Samantha Gillard
P2860
P2888
P304
P356
10.1007/S40273-013-0076-Z
P577
2013-09-01T00:00:00Z